Introduction
Cardiovascular diseases like heart failure (HF) and cardiac arrhythmias (CA) form a major component of the non-communicable disease burden in the Indian population. [1] [2] [3] [4] [5] [6] [7] Approximately 40,000-50,000 CA/HF patients receive interventional device therapies like pacemakers, implantable cardioverter defibrillators (ICD), cardiac resynchronization therapy (CRT) and/or radiofrequency ablation (RFA) annually in India. [8] [9] [10] However, there is very limited published information that systematically profiles Indian HF and CA patients. There is virtually no insight into the diagnostic and interventional treatment access process for these patients.
We implemented a clinical registry that enrolled 2205 CA/HF patients presenting to 59 non-interventional consulting physicians (CP) across 12 cities in India and used a diagnosis protocol (DP) to characterize their demographic, cardiovascular, interventional device/RFA therapy indication profiles and referral/consultation patterns. The results from such a registry could provide a basis for healthcare practitioners, policy makers, payers and medical administrations for improving the overall management and access to treatment for patients suffering from CA and HF. Also, the information gained from the registry could be used to increase physician awareness, diagnosis & therapy prescription and outline improved processes for HF and CA management.
Methods
The PANARM HF registry, a prospective, multi-center, noninterventional, observational study was conducted Two categories of physicians from across 12 cities in India participated in the registry: 1) 59 non-interventional CP who were MD's or non-interventional cardiologists by qualification, and 2) 16 interventional cardiologists (IC) who were expert practitioners of implantable device therapy, and in several cases, who also perform RFA.
A detailed diagnosis protocol (DP) comprising history and symptom assessment, physical exam, ECG, echocardiographic testing (where applicable) and consensus-guidelines based interventional therapy indication assessment was defined by a group of IC's to classify patients suffering from CA and/or HF and interventional therapy options for these patients. Cardiac arrhythmia and heart failure patients analyzed in the registry were classified as defined in Table 1 . The ACC/AHA/HRS ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities 8 were used to identify patients indicated for pacemaker, ICD and CRT. The ACC/AHA Guidelines for Clinical Intracardiac Electrophysiological and Catheter Ablation Procedures 9 were used to identify patients indicated for RFA. All participating CP's were trained on implementing the DP by IC's during study training meetings that preceded CP enrollment into the study. In addition, a variety of educational tools were provided to the CP to supplement the DP and aid in the diagnosis & therapy assessment process .[ 1 4 6 _ T D $ D I F F ] Bimonthly study review meetings between ICs and their assigned CPs were encouraged. Fig. 1 shows a flow chart of the study process. CP's evaluated all patients presenting to them and identified patients eligible for enrolment according to the following inclusion criteria: 1) patients with one or more of the following symptoms secondary to CA and/or HF -syncope, pre-syncope, dyspnea, palpitations, fatigue, and/or 2) left ventricular dysfunction (left ventricular ejection fraction (LVEF) 40% measured through echocardiogram), 3) patients who had signed and dated a Patient Data Release Form specified in this study plan, and 4) patients who were at least 18 years of age at the time of enrolment. The following patients were excluded: 1) patients with HF arising out of primary valvular diseases 2) patients with acute myocardial infarction [ 1 4 7 _ T D $ D I F F ] A CP case report form (CP CRF) that captured the patient's demographic, symptom, cardiovascular, disease etiology and therapy indication profile, including ECG for all patients and echocardiographic report for patients with LV dysfunction were completed for all enrolled patients by the CP. All patients who required further evaluation by IC for implantable device therapy/ RF ablation in the CP's judgment were counselled and referred to the CP's designated IC participating in the registry for further evaluation and treatment. Patients who did not require interventional therapy in the CP's judgment were not referred to the IC and were prescribed drug management by the CP.
CP CRF, ECG and echo reports for all patients, both referred and not referred by the CP, were transferred to designated IC from the CP on a monthly basis. IC's recorded the final diagnosis, disease etiology and therapy prescription in an IC CRF for each patient. All information recorded in the CP CRF and IC CRF was analyzed to construct detailed demographic, clinical and device/RFA therapy indication profiles for CA/HF patients presenting to the CP. Continuous data are reported as mean and standard deviation. Categorical data are reported as frequencies (N) and percentages (%). This was a non-comparative study and therefore no statistical testing was performed.
Results
2205 patients who met study inclusion/exclusion criteria were enrolled in the study. An average of 37 patients was enrolled per CP by the 59 CP contributing to the study population. Table 2 shows the clinical and demographic profiles of the total registry population and Table 3 that of the HF sub-population. Fatigue, dyspnea and palpitations were the most common symptoms, 76% patients having multiple symptoms and 30% of patients had experienced syncope/pre-syncope. 51 (2%) patients did not have symptoms at the time of enrollment and were included in the study because they had LV dysfunction.
Demographic and clinical profile
With 1272 (58%) registry patients suffering from HF, it was the most prevalent syndrome followed by bradyarrhythmia 15%, atrial fibrillation -15%, other supraventricular tachyarrhythmia -10% and ventricular tachycardia/fibrillation -4.5%. Approximately 401 (31%) patients of the HF population were also at high risk for Sudden Cardiac Arrest (SCA). The majority of the HF population was in an advanced state of HF, with about 1042 (82%) patients being in Stage C and D, 814 (64%) with LVEF 30% and 486 (38%) patients with a QRS width !120 ms.
The bradyarrhythmia population totalled 266 (12%) patients (mean age 63.5 AE 13.5),with 146 (55%) Sinus Node Dysfunction (SND) patients and 120 (45%) 2nd and 3rd degree AV block patients. The SND patients were significantly symptomatic with 79% presenting with syncope/pre-syncope, 62% with fatigue and 48% with dyspnea greater than New York Heart Association (NYHA) Class II. 19% of SND patients had LV dysfunction with EF 40%. Higher incidence of SND was observed from the 6th decade onwards and AV block a decade earlier. In addition to syncope, fatigue was a significant symptom in both SND and AV block.
20% of the registry population had suffered a prior MI and about 52% were known to have CAD. 
Therapy recommendation and patient referral patterns
As shown in Fig. 2 , 1011 out of 2205 ($46%) patients were identified to potentially benefit from pacemaker, ICD, CRT or RFA by the IC. Nearly 50% of the registry patients were identified for medical management only and about 5% needed further evaluation. 11 patients were identified for procedures like revascularization, valve repair/replacement etc. that were outside the scope of this study. In particular, 289/1272 (23%) of the HF patients and 722/ 1379 (52.4%) of CA patients were classified by IC's as potentially needing interventional device or RFA therapy.
Analysis of the CP referral patterns for the 1011 patients identified by the IC as potentially benefitting from interventional showed that only 700 (69%) of these patients were referred to the IC by their CP and [ 1 5 1 _ T D $ D I F F ] 311 (31%) were not. Analysis of the IC consultation patterns for the 700 referred patients showed that only 177 ($25% of referred patients) consulted the IC -the remaining 523 patients identified by the CP and another [ 1 5 2 _ T D $ D I F F ] 311 not identified by the CP, who could have potentially benefitted from interventional therapy did not consult the IC to whom they were referred within the duration of the study. Thus, only the 177 patients who consulted the IC were actually prescribed therapy, while for the remaining [ 1 5 3 _ T D $ D I F F ] 834 patients who could have benefitted from interventional therapy, the opportunity to receive this therapy was unavailable. This referral, consultation and prescription pattern is depicted in Fig. 3 .
Discussion
To our knowledge, the PANARM HF registry represents the first study that characterizes the demographic, cardiovascular, interventional device or RFA therapy indication profiles and referral/ specialist consultation patterns of over 2000 patients with HF and/ or CA symptoms presenting to non-interventional consulting physicians across India. Percentages are calculated on the basis of patients with collected information.
Demographic and clinical profile of arrhythmia and heart failure patients
The majority of the patients (62%) were male. A similar gender ratio was shown in the 11th World pacing survey 11 in patients receiving pacemaker implants in India. The imbalance between male and female recipients of implantable devices or interventional therapies is much lower in the developed world.
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In India this imbalance could be due to a combination of factors such as reduced cardiovascular disease prevalence amongst females, reluctance to seek healthcare and, more likely, a lower priority and willingness to finance female health in Indian society. Close to half the population was 60 years, which is lower compared to similar cohorts in other parts of the world.
11-13 Data from the Framingham Heart Study indicate that the mean age at the diagnosis of HF was 70 years. 12 In the western population the average age of patients receiving pacemakers for SND is about 75 years. 13 This is an important finding of our study which indicates an early disease onset, which aligns well with premature onset of cardio-vascular risk factors and lower average life-span of 67 years for males and 69 years for females in India.
14 Prevalence of heart failure (58%) and cardiac arrhythmias (22% at high risk for SCA, 15% suffering from atrial fibrillation, 15% from bradyarrhythmia) in our study of course derive from the study design and selection criteria. It is noteworthy that a significant percentage (>50%) of patients with HF or CA symptoms were actually found in a fairly advanced stage of cardiovascular disease, as shown by the fact that 82% of HF patients were in stage C or D HF and 722/1379 (52.4%) CA patients were candidates for Given the high proportion of patients with LV dysfunction in the registry, a significant cohort of 401 registry patients (18%) had a clinical profile that placed them in the primary prevention risk category for SCA. 46% of these patients had non-ischemic cardiomyopathy which is higher in comparison to registries that studied patients indicated for ICD therapy for SCA primary prevention from other parts of the world. 13 The non-ischemic group was younger (34.5% 51 years), had a higher ratio of females, lower hypertension and diabetes but a higher percentage of patients with a broad QRS. These patients could represent a high focus group for therapy access due to the potentially higher benefit they may gain from cardiac resynchronization therapy as compared to the more co-morbid and advanced-in stage ischemic cardiomyopathy patients.
Of the 2205 patients enrolled in the study, 331 (15%) patients suffered from bradyarrhythmias, with a higher percentage of SND patients (44%) compared to heart block patients (36%). The 11th World pacing survey 11 showed only 23% of patients receiving pacemakers in India for SND versus 58% for advance heart blocks.
Thus, it appears that despite being symptomatic, a significant proportion of SND patients do not receive pacemakers in India, likely due to the relatively benign nature of the disease and limited severity of their symptoms. The age distribution of the SND population indicated that 70% of the patients were below the age of 70, whereas in the western population the average age of patients receiving pacemakers for SND was 75. Atrial fibrillation or other supraventricular tachyarrhythmias were documented in 551 (25%) patients. The actual prevalence of atrial tachyarrhythmias in the evaluated patients is probably higher due to undocumented intermittent and asymptomatic forms of tachyarrhythmias. 70% of the AF patients were below the age of 70, indicating an earlier onset of disease compared to in the west. 13 The percentage of women was relatively higher in this cohort, at 48% versus an overall female study representation of 38%.
Interventional therapy indication
Out of 2205 patients, selected only on the basis of HF and/or CA symptoms, 1011 (45.8%) could benefit from interventional device therapy/ablation. As shown in Fig. 2 , the percentage of patients indicated for interventional therapy varied according to their disease condition, ranging from 23% for HF patients, 34% of AF/SVT patients, 55% for bradycardia patients and 73% for patients with primary and secondary SCA risk. The cost of these devices and therapies is a limiting factor in the Indian healthcare system and these therapies are beyond the reach of many patients. However, those who can afford them should be referred to centres and cardiologists experienced in performing these interventional therapies.
Referral patterns and therapy adoption
Large volumes of advanced cardiovascular diseases are managed by CP in [ 1 6 2 _ T D $ D I F F ] India. Before the study started, CP were characterized by large differences in the knowledge and application of diagnosis, ECG analysis and interventional therapy guidelines for CA/HF patients. The study training programs, diagnostic protocol and tools were deemed of significant value by the CP in enhancing their knowledge and systematizing their approach to patient screening, diagnosis, counselling and referral.
Despite this training, [ 1 6 3 _ T D $ D I F F ] 311/1011 (31%) patients who could benefit from interventional therapy were not referred to IC, as shown in Fig. 3 . Similarly 50% of patients who did not need interventional therapy were unnecessarily referred to the IC. Of 1011 patients who could have benefited from interventional therapy, only 177 consulted IC's (17%) due to both inadequate referral (only 69% of patients requiring interventional were referred by CP to IC) as well as poor IC consultation compliance by referred patient (Fig. 3) . Since correct identification of indicated patients and patient counselling were issues at the CP level, our data suggest the need for continuous education strategies and simple diagnostic algorithms for improved screening and diagnosis at physician level and for enhanced patient counselling.
In particular our study indicates that CP in India manage significant volumes of primary prevention for SCA patients, many of them with relatively early disease onset and non-ischemic etiology. Unfortunately only a minority of ICD indicated patients were referred and actually received an ICD. ICD therapy for patients meeting primary prevention consensus guidelines is significantly under-utilized all over the world.
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The key study results are 1) a significant portion of the study population, selected for having HF and CA symptoms, was found in a fairly advanced stage of cardiovascular disease at the time they consulted the physician, 2) almost half the patients with HF and/or CA symptoms would warrant an interventional device therapy or ablation but 3) even in the study controlled environment only 17% of indicated patients consulted an interventional specialist and were prescribed with an interventional therapy.
The study provides substantial new information about health care gaps in India and meaningful insights that can be applied to enhance diagnosis, therapy access and management of these patients. Our results may be valuable for healthcare providers, policy makers, payers and medical administrations to define and implement strategies focused on reducing the disease burden of HF and CA. Our data suggest to focus on enhancing identification, counselling and referral of CA/HF patients indicated for interventional therapy by consulting physicians to specialists who can provide these therapies. In addition, initiatives toward patients education are warranted. The fact that the majority of patients consult physicians only after disease has progressed to advanced stage, as shown in our data, suggest the need for improving patient awareness about cardiovascular diseases and enhancing patients' attitude toward proactive healthcare seeking behaviour through frequent consultation with specialists and acceptance of therapy upon prescription. Finally, it is important for the government, care providers, reimbursement groups, medical insurance and industry to establish innovative programs to address affordability and liquidity barriers that prevent patients prescribed interventional therapies from adopting them.
Limitations
This was a prospective observational research. The limitations of multicentre observational studies, such as potential bias in patient selection and patient referral and the lack of a control group, apply to our research. The fact that the study was preceded by training on diagnosis and therapy guidelines and that research endpoints were pre-specified possibly mitigated patient selection and referral biases In addition, the results of the study are limited to the evaluated population of subjects with HF and/or CA symptoms.
Conclusions
Through an observational study we found that a significant portion of patients with HF or CA symptoms, presenting to noninterventional consulting physicians across 12 cities in India, was in a fairly advanced stage of cardiovascular disease. In fact almost half the patients were indicated for interventional device therapy or ablation. We found that, even in the study controlled environment, only a minority (17%) are prescribed the indicated interventional therapy. In particular, while therapy penetration was fair for pacemaker and RF ablation therapy, it was minimal for CRT and ICD. Healthcare quality improvement strategies are warranted to reduce the HF and CA disease burden.
Funding sources
The study was sponsored by India Medtronic Pvt. Ltd. which performed study management and data management tasks and contributed to the review of data analysis report and manuscript contents for technical aspects. The sponsor had no role in the collection of clinical data and in the interpretation of data.
Acknowledgements
We thank the Panarrhythmia and Heart Failure Observational Study team at Medtronic India for their support; and the monitors, investigators, study coordinators, and patients for having done this trial. We also thank [ 1 6 4 _ T D $ D I F F ] the employees of Medtronic India, for their assistance throughout the conduct of the study.
Medical writing and editorial assistance in the preparation of this paper, funded by Medtronic India, was provided by Andrea Grammatico (Medtronic EMEA Regional Clinical Centre, Rome, Italy). 
